



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
production.office@frontiersin.org

SPECIALTY SECTION
This article was submitted to
Clinical Nutrition,
a section of the journal
Frontiers in Nutrition

RECEIVED 07 November 2022
ACCEPTED 07 November 2022
PUBLISHED 07 December 2022

CITATION
Frontiers Production Office (2022)
Erratum: Impact of fibre and
red/processed meat intake on
treatment outcomes among patients
with chronic inflammatory diseases
initiating biological therapy: A
prospective cohort study.
Front. Nutr. 9:1091846.
doi: 10.3389/fnut.2022.1091846

COPYRIGHT
© 2022 Frontiers Production Office.
This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Erratum: Impact of fibre and red/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: A prospective cohort study

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

chronic inflammatory disease, biologic therapy, diet, red meat, fibre, processed meat, rheumatoid arthritis, inflammatory bowel disease

An Erratum on

Impact of fibre and red/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: A prospective cohort study

by Overgaard, S. H., Sørensen, S. B., Munk, H. L., Nexøe, A. B., Glerup, H., Henriksen, R. H., Guldmann, T., Pedersen, N., Saboori, S., Hvid, L., Dahlerup, J. F., Hvas, C. L., Jawhara, M., Andersen, K. W., Pedersen, A. K., Nielsen, O. H., Bergenheim, F., Brodersen, J. B., Heitmann, B. L., Halldorsson, T. I., Holmskov, U., Bygum, A., Christensen, R., Kjeldsen, J., Ellingsen, T., and Andersen, V. (2022). *Front. Nutr.* 9:985732. doi: 10.3389/fnut.2022.985732

Due to a production error, there was a mistake in the legend for Figure 1 as published. The legend for Figure 2 was incorrectly used in its place. The correct legend appears below.

Flow chart of the enrolment of participants. Number of Chronic Inflammatory Disease patients who were screened, included in the study and included in the analysis. Patients screened for eligibility were not explicitly recorded in the study. For CD, UC, and PsO we estimated a number based on the mean inclusion rate from two clinics that kept a pre-screening log. For RA, axSpA, and PsA, the number is not an estimate but the total number of patients that initiated biologic treatment in the clinic during enrolment. IBD, Inflammatory bowel disease (Crohn's disease and Ulcerative colitis); CD, Crohn's disease; UC, Ulcerative colitis; RA, Rheumatoid arthritis; axSpA, Axial spondyloarthritis; PsA, Psoriatic arthritis; PsO, Psoriasis; FFQ, Food Frequency Questionnaire; HFLM, high fibre/low meat; LFHM, low fibre/high meat; ITT, intention-to-treat; SF-12 PCS + MCS, short form health survey the physical and mental component summary, The

short health scale includes four health dimensions (symptom burden, functional status, disease-related burden and general wellbeing); CRP, C-reactive protein.

Due to a production error, there was a mistake in the legend for Figure 2 as published. The legend for Figure 1 was incorrectly used in its place. The correct legend appears below.

Meta-analysis (random effects model) of the included Chronic Inflammatory Diseases (CIDs) on the “As Observed” population comparing clinical response to biologics in patients with a high intake of fibre and low intake of red/processed meat (HFLM) vs. patients with a low intake of fibre and high intake of red/processed meat (LFHM). The horizontal lines represent the odds ratio (OR) \pm 95% confidence interval. Event = clinical response according to the specified criteria for each CID, i.e., the number shows how many out of the total number

of participants in the group, that have had a clinical response. The “As Observed” populations means patients with complete data for clinical response (i.e., 17 patients are excluded).

The publisher apologizes for this mistake. The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.